**WASHINGTON D.C. –** The U.S. Food and Drug Administration (FDA) announced on April 1, 2026, the approval of Eli Lilly and Company's Foundayo (orforglipron), a novel once-daily oral medication for chronic weight management. Foundayo distinguishes itself as the first glucagon-like peptide-1 (GLP-1) pill that can be taken at any time of day, completely free of food or water restrictions, a significant development in the burgeoning field of obesity pharmacotherapy. This landmark approval offers a new, more convenient option for millions of adults grappling with obesity or who are overweight with at least one weight-related medical condition.

The approval of Foundayo is based on data from the comprehensive ATTAIN Phase 3 global clinical development program, which included the ATTAIN-1 and ATTAIN-2 trials. In the ATTAIN-1 trial, which involved adults without diabetes, participants receiving the highest dose of Foundayo achieved an average weight loss of 27 pounds, or 12.4% of their body weight, over 72 weeks. This was a substantial improvement compared to the average 2.2 pounds, or 0.9% body weight loss, observed in the placebo group over the same period. Foundayo is approved for use in conjunction with a reduced-calorie diet and increased physical activity.

Foundayo's unique "small molecule" design, as opposed to the peptide-based structure of some other GLP-1 receptor agonists, allows for its unprecedented flexibility in dosing. "People taking orforglipron do not need to restrict food or drink after taking the pill," explained Dr. Dan Skovronsky, Eli Lilly's chief scientific and product officer. This stands in stark contrast to oral semaglutide (Wegovy pill) from Novo Nordisk, approved in December 2025, which necessitates taking the pill on an empty stomach with a limited amount of water and then waiting 30 minutes before eating or drinking. Deborah Horn, DO, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, emphasized the practical benefit, stating, "for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment."

The introduction of oral GLP-1 medications represents a significant shift in the obesity treatment landscape, which has historically relied on injectable therapies like Lilly's Zepbound and Mounjaro, and Novo Nordisk's injectable Wegovy. While these injectables have demonstrated high efficacy, barriers such as cost, stigma, and the inconvenience of injections have limited broader access and adherence. Eli Lilly CEO David Ricks expressed "broad ambitions" for Foundayo, noting that fewer than 1 in 10 people who could benefit from a GLP-1 therapy are currently utilizing one. The convenience of a pill-based treatment is expected to significantly enhance patient adherence and make GLP-1 therapies more accessible.

Eli Lilly has moved swiftly to make Foundayo available, with prescriptions now being accepted via LillyDirect with free home delivery, and shipments commencing as early as April 6, 2026. Broader availability through U.S. retail pharmacies and telehealth providers is expected to follow shortly thereafter. To address affordability, Eli Lilly has announced a savings program allowing eligible commercially insured patients to pay as little as $25 per month. For self-pay patients, the medication will start at $149 per month, and eligible Medicare Part D individuals may gain access for approximately $50 per month starting July 1, 2026. This accelerated approval came through the FDA's Commissioner's National Priority Voucher program, which expedited the review process, resulting in approval just 100 days after submission.

While Foundayo offers a compelling new option, patients should be aware of potential side effects, which are largely consistent with other GLP-1 receptor agonists. These commonly include gastrointestinal issues such as nausea, constipation, vomiting, diarrhea, and indigestion, with rare instances of an increased risk of thyroid cancer. Looking ahead, the approval of Foundayo intensifies competition in the weight loss market, pushing innovation and potentially leading to more diverse and accessible treatment options. Eli Lilly has indicated further research into additional indications for orforglipron, including sleep apnea, hypertension, and stress urinary incontinence, signaling its potential as a foundational therapy for a range of cardiometabolic conditions beyond obesity.